Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Company’s initial public offering conducted on February 7, 2024 (the “IPO”). Kyverna is a “clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.”

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Misled Investors Regarding its Business Operations.

According to the lawsuit, the registration statement and prospectus used to effectuate Kyverna’s IPO misstated and/or omitted facts concerning the results of Kyverna’s ongoing evaluation of KYV-101, Kyverna’s lead product candidate, in clinical trials. Specifically, Kyverna touted patient “improvement” in certain indicators while failing to disclose adverse data regarding one of Kyverna’s trials, which adverse data was known to Kyverna at the time of the IPO. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Kyverna Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by February 7, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210356721/en/